Table 2.
Human cell | Canonical Markers | Alternative markers | Negative markers | Localization | Differentiation potential | Additional comments | References |
---|---|---|---|---|---|---|---|
Embryonic-fetal FAPs | PDGFRA |
DCN FN1 LUM OSR1 POSTN FAP THY1/CD90 VIM NT5E/CD73 COL1A1 COL1A2 COL3A1 PTN OGN FBLN5 |
PAX3 PAX7 |
Similar to what is found in mouse development, although not evaluated in detail | Not evaluated but probably similar to what is found in mouse development | No information about their origin, gene regulation, function, and potency | [70]a |
Adult FAPs | PDGFRA, CD34 (when negative for CD56, CD31 and CD45) |
CD201 CD166 CD105 CD90 CD73 CD34 CD15 COL1A1 TCF7L2/TCF4 |
CD31 CD45 CD56 α7-Integrin NG2/CSPG4 RSG5 |
Fascia, epimysium, perimysium, and endomysium; abundant as perivascular cells | Adipocytes, myofibroblasts, osteocytes, and chondrocytes in diseased states and in vitro. Lack of myogenic potential | Increased numbers in diverse pathologies | [16]; [51]; [71]; [72]; [52]; [53, 54, 64] |
aThese other alternative markers suggested by Pyle and colleagues are based on scRNAseq data (Xi et al., [70])